Updated efficacy of lenvatinib (LEN) plus pembrolizumab (PEMBRO) versus sunitinib (SUN) in patients with advanced renal cell carcinoma (aRCC) in the CLEAR study

被引：0

作者：

Porta, Camillo G. ^{[1
]}

Eto, Masatoshi ^{[2
]}

Motzer, Robert J. ^{[3
]}

De Giorgi, Ugo ^{[4
]}

Buchler, Tomas ^{[5
]}

Basappa, Naveen S. ^{[6
]}

Mendez Vidal, Maria Jose ^{[7
]}

Tjulandin, Sergei ^{[8
]}

Park, Se Hoon ^{[9
]}

Melichar, Bohuslav ^{[10
]}

Hutson, Thomas ^{[11
,12
]}

Alemany, Carlos ^{[13
]}

McGregor, Bradley ^{[14
]}

He, Cixin Steven ^{[15
]}

Perini, Rodolfo ^{[16
]}

Mody, Kalgi ^{[15
]}

McKenzie, Jodi ^{[15
]}

Ebaid, Basant ^{[17
]}

Choueiri, Toni ^{[14
]}

机构：

[1] Univ Bari A Moro, Interdisciplinary Dept Med, Bari, Italy

[2] Kyushu Univ, Dept Urol, Fukuoka, Japan

[3] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA

[4] IRCCS Ist Romagnolo Tumouri IRST Dino Amadori, Dept Med Oncol, Meldola, Italy

[5] Thomayer Univ Hosp, Dept Oncol, Prague, Czech Republic

[6] Univ Alberta, Cross Canc Inst, Dept Med Oncol, Edmonton, AB, Canada

[7] Hosp Univ Reina Sofia, Maimonides Inst Biomed Res Cordoba, Dept Med Oncol, Cordoba, Spain

[8] Minist Hlth Russian Federat, Dept Clin Pharmacol & Chemotherapy, NN Blokhin Natl Med Res Ctr Oncol, Moscow, Russia

[9] Sungkyunkwan Univ, Div Hematol Oncol, Dept Med, Samsung Med Ctr,Sch Med, Seoul, South Korea

[10] Palacky Univ Med Sch & Teaching Hosp, Dept Oncol, Olomouc, Czech Republic

[11] Texas Oncol Baylor Charles A Sammons Canc Ctr, Dept Med Oncol, Dallas, TX USA

[12] Texas A&M HSC Coll Med, Bryan, TX USA

[13] Advent Hlth Canc Inst, Dept Hematol & Oncol, Orlando, FL USA

[14] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA

[15] Eisai Inc, Nutley, NJ USA

[16] Merck & Co Inc, Rahway, NJ USA

[17] Eisai Australia Pty Ltd, Melbourne, Australia

来源：

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 18卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

197

引用

页码：122 / 123

页数：2

共 50 条

[1] Updated efficacy of lenvatinib (LEN) plus pembrolizumab (PEMBRO) vs sunitinib (SUN) in patients (pts) with advanced renal cell carcinoma (aRCC) in the CLEAR study
Porta, C. G.
Eto, M.
Motzer, R. J.
De Giorgi, U. F. F.
Buchler, T.
Basappa, N. S.
Mendez Vidal, M. J.
Tjulandin, S.
Park, S. H.
Melichar, B.
Hutson, T. E.
Alemany, C.
McGregor, B.
He, C. S.
Perini, R.
Mody, K.
McKenzie, J.
Choueiri, T. K.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1205 - +
[2] Impact of subsequent therapies in patients (pts) with advanced renal cell carcinoma (aRCC) receiving lenvatinib plus pembrolizumab (LEN plus PEMBRO) or sunitinib (SUN) in the CLEAR study.
Voss, Martin H.
Powles, Thomas
McGregor, Bradley Alexander
Porta, Camillo
Gruenwald, Viktor
Merchan, Jaime R.
Rolland, Frederic
Maroto-Rey, Pablo
Goh, Jeffrey C.
Xing, Dongyuan
Perini, Rodolfo F.
McKenzie, Jodi
Mody, Kalgi
Motzer, Robert J.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[3] Efficacy and safety of lenvatinib (LEN) plus pembrolizumab (PEMBRO) versus sunitinib (SUN) in the East Asian subset of patients with advanced renal cell carcinoma (aRCC) from the phase 3 CLEAR trial.
Rha, Sun Young
Choueiri, Toni K.
Matveev, Vsevolod B.
Alyasova, Anna
Hong, Sung-Hoo
Gordoa, Teresa Alonso
Gurney, Howard
Bjarnason, Georg A.
Buchler, Tomas
Pedrazzoli, Paolo
Takagi, Toshio
Park, Se Hoon
Lee, Jae-Lyun
Perini, Rodolfo F.
He, Cixin
McKenzie, Jodi A.
Eto, Masatoshi
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
[4] Analysis of the CLEAR study in patients (pts) with advanced renal cell carcinoma (RCC): Depth of response and efficacy for selected subgroups in the lenvatinib (LEN) plus pembrolizumab (PEMBRO) and sunitinib (SUN) treatment arms.
Grunwald, Viktor
Powles, Thomas
Kopyltsov, Evgeny
Kozlov, Vadim
Gordoa, Teresa Alonso
Eto, Masatoshi
Hutson, Thomas E.
Motzer, Robert J.
Winquist, Eric
Maroto-Rey, Pablo
Keam, Bhumsuk
Procopio, Giuseppe
Wong, Shirley
Melichar, Bohuslav
Rolland, Frederic
Oya, Mototsugu
Rodriguez-Lopez, Karla
Saito, Kenichi
Smith, Alan D.
Porta, Camillo
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[5] Phase 3 trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) monotherapy as a firstline treatment for patients (pts) with advanced renal cell carcinoma (RCC) (CLEAR study).
Motzer, Robert J.
Porta, Camillo
Eto, Masatoshi
Powles, Thomas
Grunwald, Viktor
Hutson, Thomas E.
Alekseev, Boris
Rha, Sun Young
Kopyltsov, Evgeny
Mendez Vidal, Maria Jose
Hong, Sung-Hoo
Kapoor, Anil
Gordoa, Teresa Alonso
Goh, Jeffrey C.
Merchan, Jaime R.
Smith, Alan D.
Mody, Kalgi
Perini, Rodolfo F.
Xing Dongyuan
Choueiri, Toni K.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
[6] Lenvatinib plus pembrolizumab versus sunitinib for advanced renal cell carcinoma: Japanese patients from the CLEAR study
Eto, Masatoshi
Takagi, Toshio
Kimura, Go
Fukasawa, Satoshi
Tamada, Satoshi
Miura, Yuji
Oya, Mototsugu
Sassa, Naoto
Anai, Satoshi
Nozawa, Masahiro
Sakai, Hideki
Perini, Rodolfo
Yusa, Wataru
Ikezawa, Hiroki
Narita, Tomoyuki
Tomita, Yoshihiko
CANCER MEDICINE, 2023, 12 (06): : 6902 - 6912
[7] Health-related quality-of-life (HRQoL) analysis from the phase 3 CLEAR trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) for patients (pts) with advanced renal cell carcinoma (aRCC).
Motzer, Robert J.
Porta, Camillo
Alekseev, Boris
Rha, Sun Young
Choueiri, Toni K.
Mendez-Vidal, Maria Jose
Hong, Sung-Hoo
Kapoor, Anil
Goh, Jeffrey C.
Eto, Masatoshi
Wang, Jinyi
Pan, Janice
Asfaw, Alemseged Ayele
He, Cixin Steven
Mody, Kalgi
Cella, David
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[8] Genomic biomarkers of response to lenvatinib/pembrolizumab (Len/Pembro) in patients with advanced renal cell carcinoma
Lee, Chung-Han
DiNatale, Renzo G.
Chowell, Diego
Krishna, Chriag
Makarov, Vladimir
Shapnik, Natalie
Murray, Samuel J.
Carlo, Maria Isabel
Voss, Martin H.
Feldman, Darren R.
Hakimi, A. Ari
Adachi, Yusuke
Minoshima, Yukinori
Matsui, Junji
Funahashi, Yasuhiro
Perini, Rodolfo F.
Nomoto, Kenichi
Motzer, Robert J.
Chan, Timothy An-thy
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
[9] Outcomes of patients (pts) with advanced renal cell carcinoma (aRCC) treated with cabozantinib (CABO) after lenvatinib plus pembrolizumab (LEN plus PEM).
Haro-Silerio, Jaime Ivan
Johns, Andrew
Moussa, Mohammad Jad
Wang, Mindy
Wang, Emily
Kovitz, Craig A.
Campbell, Matthew T.
Jonasch, Eric
Shah, Amishi Yogesh
Tannir, Nizar M.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 433 - 433
[10] Characterization and management of adverse reactions (ARs) in patients with advanced renal cell carcinoma (aRCC) receiving lenvatinib plus pembrolizumab (CLEAR study)
Motzer, Robert
George, Saby
Merchan, Jaime R.
Hutson, Thomas E.
Song, Xun
Perini, Rodolfo F.
Xie, Ran
Bapat, Urmi
Ebaid, Basant
Puente, Javier
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 121 - 122

← 1 2 3 4 5 →